Opsis Therapeutics
PrivateLast Round
Corporate Funding
May 17, 2021
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Opsis Therapeutics is a biotechnology company that develops cell replacement therapies for ocular diseases using induced pluripotent stem cell (iPSC) technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Opsis Therapeutics Comparables
Compare Opsis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Agnos Therapeutics | 93% | |
| Luxa Biotechnology | 88% | |
| Regenerative Patch Technologies | 86% | |
Opsis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | May 17, 2021 | ||||
| Seed | Jul 31, 2016 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 66% MoM, reaching 3.2K.
- Jun 19, 2026
Monthly visitors grew 118% MoM, reaching 1.9K.
Opsis Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Opsis Therapeutics's valuation, stock price, and market status.